| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Gwang Hyeon Choi, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, In Hee Kim, Sung Bum Cho, Han Chu Lee, Jeong Won Jang, Moran Ki, Hwa Young Choi, Dahye Baik and Sook‐Hyang Jeong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Chronic Infectious Disease Cohort Study (Korea HCV Cohort Study) from the National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency |
2020-E5104-02 |
|
| Corresponding Author |
Sook‐Hyang Jeong, PhD, Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam 13620, South Korea. jsh@snubh.org |
| Key Words |
Hepatitis C virus; Direct-acting antiviral; Sustained virologic response; Hepatocellular carcinoma; Mortality |
| Core Tip |
Treatment and sustained virologic response (SVR) with either interferon-based treatment (IBT) or direct-acting antiviral (DAA) significantly reduced the incidences of hepatocellular carcinoma and mortality in our Asian prospective cohort. The risks of HCC and all-cause of mortality were not significantly different regardless of whether SVR was induced by IBT or DAA. After achieving SVR, age, the presence of cirrhosis, and genotype 1 hepatitis C virus infection were indicators of worse clinical outcomes. |
| Publish Date |
2022-08-10 08:23 |
| Citation |
Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Jang JW, Ki M, Choi HY, Baik D, Jeong SH. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. World J Gastroenterol 2022; 28(30): 4182-4200 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i30/4182.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i30.4182 |
